Eli Lilly and Company $LLY Stock Position Increased by Varma Mutual Pension Insurance Co

Varma Mutual Pension Insurance Co raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 11.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 121,468 shares of the company’s stock after purchasing an additional 12,200 shares during the period. Eli Lilly and Company accounts for approximately 0.6% of Varma Mutual Pension Insurance Co’s holdings, making the stock its 21st biggest position. Varma Mutual Pension Insurance Co’s holdings in Eli Lilly and Company were worth $92,680,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in LLY. Vanguard Group Inc. increased its position in Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after acquiring an additional 1,183,038 shares during the period. Laurel Wealth Advisors LLC grew its stake in shares of Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank acquired a new position in shares of Eli Lilly and Company during the second quarter valued at $8,827,714,000. Jennison Associates LLC raised its stake in shares of Eli Lilly and Company by 4.3% during the second quarter. Jennison Associates LLC now owns 5,447,636 shares of the company’s stock valued at $4,246,596,000 after purchasing an additional 226,620 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Eli Lilly and Company by 2.0% in the second quarter. Charles Schwab Investment Management Inc. now owns 5,359,653 shares of the company’s stock worth $4,178,010,000 after purchasing an additional 103,119 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 0.9%

Shares of Eli Lilly and Company stock opened at $1,015.48 on Thursday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The firm has a market capitalization of $960.02 billion, a PE ratio of 44.25, a price-to-earnings-growth ratio of 0.94 and a beta of 0.39. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The stock’s fifty day moving average is $1,051.24 and its 200-day moving average is $903.76.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 112.50%. The company had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period in the prior year, the firm earned $5.32 earnings per share. The business’s quarterly revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 26.14%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion, expanding its in‑vivo CAR‑T and circular RNA capabilities and diversifying beyond GLP‑1s — a strategic, long‑term pipeline bet. Article Title
• Positive Sentiment: Clinical progress: Lilly reported advancement of solbinsiran in high‑risk cholesterol studies and moved eloralintide into Phase 3, broadening non‑GLP therapeutic opportunities. These data/catalysts can support future revenue streams. Article Title Article Title
• Positive Sentiment: Institutional support: Fisher Asset Management increased its LLY stake, and the Baron Opportunity Fund cited Lilly (driven by Zepbound) as a contributor — signs of investor conviction. Article Title Article Title
• Positive Sentiment: Analyst upgrade: Freedom Capital raised Lilly to a “strong‑buy” (reported via Zacks), which can support sentiment and buying interest. Article Title
• Neutral Sentiment: Macro/market coverage: Multiple pieces assess Lilly vs Novo Nordisk in the large weight‑loss market (potentially ~$100B). These explain market opportunity and competitive dynamics but don’t change fundamentals by themselves. Article Title
• Neutral Sentiment: Partnerships and R&D collaborations (e.g., with gene‑editing start‑ups) continue to expand Lilly’s discovery engine; important longer‑term but incremental near term. Article Title
• Neutral Sentiment: Local growth: Huntsville council set to vote on a Lilly development — could support manufacturing/ops expansion if approved, but is a localized item. Article Title
• Negative Sentiment: Competitive pressure: Novo Nordisk plans packaging/format moves (selling obesity shot in vials) that mirror Lilly’s strategies — a sign competition is intensifying, which could pressure pricing and market share over time. Article Title

Analyst Ratings Changes

Several research firms have commented on LLY. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Truist Financial set a $1,281.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Cantor Fitzgerald raised their price objective on shares of Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a research note on Thursday, February 5th. Scotiabank restated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Eli Lilly and Company from $1,200.00 to $1,285.00 and gave the company a “buy” rating in a research note on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,217.71.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.